Also found in: Dictionary, Thesaurus, Medical, Encyclopedia, Wikipedia.
CLLChronic Lymphocytic Leukemia
CLLCommunication Language and Literacy
CLLCollege Station, TX, USA (Airport Code)
CLLCollege of Lifelong Learning
CLLChief of Legislative Liaison
CLLCornell Law Library
CLLCorporate Lessons Learned (USACE)
CLLChronic Lymphatic Leukemia Foundation
CLLClub du Livre Libertaire (French: Libertarian Book Club)
CLLCapacitively-Loaded Loop
CLLChild Life-Line (est. 1994)
CLLCulture et Loisirs de Leuville (French: Leuville Culture and Recreation; Leuville-sur-Orge, France)
CLLCelestial Labs Ltd. (India)
References in periodicals archive ?
He concluded that students found the CLL enjoyable, helpful, and a very worthwhile experience.
Adds Bruce Cheson of the National Cancer Institute: "This really is the most exciting thing that's happened with CLL in decades.
The FDA has granted Breakthrough Therapy Designation for venetoclax for treatment of previously treated CLL patients with the 17p deletion.
CLL is a slow-growing blood cancer of white blood cells called lymphocytes, most commonly B cells.
Usually patients with highly resistant and refractory CLL would have progressed and possibly died by this time, but 82 percent remain on PCI-32765 and continue to improve," Byrd added.
ADVERSE REACTIONS The most common adverse reactions ([greater than or equal to]25%) in patients with B-cell malignancies (MCL, CLL, WM) were thrombocytopenia* (57%, 52%, 43%), neutropenia* (47%, 51%, 44%), diarrhea (51%, 48%, 37%), anemia* (41%, 36%, 13%), fatigue (41%, 28%, 21%), musculoskeletal pain (37%, 28%**, NA***), bruising (30%, 12%**, 16%**), nausea (31%, 26%, 21%), upper respiratory tract infection (34%, 16%, 19%), and rash (25%, 24%**, 22%**).
Professor Peter Hillmen, consultant haematologist at NHS Leeds Teaching Hospitals, said: "Idelalisib provides a much-needed option for those patients with CLL in whom conventional chemotherapy-based treatment are not very effective, including when the disease relapses quickly after previous therapy and for previously untreated patients with a molecular switch (17p deletion or TP53 mutation) that prevents chemotherapy being effective.
About the Phase 2 Study The Phase 2, multicenter, international, open label clinical trial was designed to evaluate the efficacy and safety of venetoclax in CLL patients with 17p deletion who relapsed, were refractory to existing therapies, or who were previously not treated for their CLL.
We used the QIAamp Circulating Nucleic Acid kit to extract ccf-DNA from 1 mL plasma from each of the CLL patients and healthy donors.
The online database PubMed, maintained by National Center for Biotechnology Information, was searched for English language articles describing case reports or case series of patients with concurrent or sequential diagnosis of PCM and CLL.
He had early-stage CLL and so we decided to monitor the disease; the patient was referred to the medical oncology department for the treatment of colon adenocarcinoma.
Clinical results show that the experimental agent ibrutinib is highly active in CLL patients.